CN120916775A - 抗癌剂、癌症治疗用药物组合物、试剂盒以及活化剂 - Google Patents

抗癌剂、癌症治疗用药物组合物、试剂盒以及活化剂

Info

Publication number
CN120916775A
CN120916775A CN202480015575.2A CN202480015575A CN120916775A CN 120916775 A CN120916775 A CN 120916775A CN 202480015575 A CN202480015575 A CN 202480015575A CN 120916775 A CN120916775 A CN 120916775A
Authority
CN
China
Prior art keywords
piv
cancer
ccl19
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480015575.2A
Other languages
English (en)
Chinese (zh)
Inventor
福村正之
大冢顺平
松川泰久
野阪哲哉
大冢智美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biokomo Corp
Mie University
Original Assignee
Biokomo Corp
Mie University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokomo Corp, Mie University filed Critical Biokomo Corp
Publication of CN120916775A publication Critical patent/CN120916775A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18733—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202480015575.2A 2023-03-01 2024-02-29 抗癌剂、癌症治疗用药物组合物、试剂盒以及活化剂 Pending CN120916775A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363449055P 2023-03-01 2023-03-01
US63/449,055 2023-03-01
PCT/JP2024/007475 WO2024181525A1 (ja) 2023-03-01 2024-02-29 抗がん剤、がん治療用医薬組成物、キット、及び活性化剤

Publications (1)

Publication Number Publication Date
CN120916775A true CN120916775A (zh) 2025-11-07

Family

ID=92589933

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480015575.2A Pending CN120916775A (zh) 2023-03-01 2024-02-29 抗癌剂、癌症治疗用药物组合物、试剂盒以及活化剂

Country Status (4)

Country Link
EP (1) EP4674421A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2024181525A1 (cg-RX-API-DMAC7.html)
CN (1) CN120916775A (cg-RX-API-DMAC7.html)
WO (1) WO2024181525A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1213004A (zh) * 1997-09-29 1999-04-07 成都拜奥生物技术研究所 重组白细胞介素-2腺病毒载体及产生方法
JP5801202B2 (ja) 2009-09-29 2015-10-28 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
JP5807917B2 (ja) 2011-02-08 2015-11-10 国立大学法人三重大学 遺伝子導入用ウイルスベクターの製造方法
JP6358706B2 (ja) 2012-12-26 2018-07-18 バイオコモ株式会社 ヒトパラインフルエンザ2型ウイルスベクターを利用したワクチン
AU2017272721B2 (en) * 2016-05-30 2023-03-30 Astellas Pharma Inc. Novel genetically engineered vaccinia viruses
KR20230100748A (ko) 2016-07-28 2023-07-05 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
CA3075886A1 (en) * 2017-10-10 2019-04-18 Yamaguchi University Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells
US20210379129A1 (en) 2018-10-09 2021-12-09 Biocomo Incorporation Anticancer agent, pharmaceutical composition for cancer treatment, and kit

Also Published As

Publication number Publication date
JPWO2024181525A1 (cg-RX-API-DMAC7.html) 2024-09-06
WO2024181525A1 (ja) 2024-09-06
EP4674421A1 (en) 2026-01-07

Similar Documents

Publication Publication Date Title
Fallon et al. The immunocytokine NHS-IL12 as a potential cancer therapeutic
Kirkwood et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma
Koya et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy
Tai et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells
Den Otter et al. Local therapy of cancer with free IL-2
JP6656349B2 (ja) 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
Jinushi et al. Enhancing the clinical activity of granulocyte‐macrophage colony‐stimulating factor‐secreting tumor cell vaccines
Colombo et al. Anti‐tumor and immunomodulatory activity of intraperitoneal IFN‐γ in ovarian carcinoma patients with minimal residual tumor after chemotherapy
Cebon et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma
Huang et al. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth
Suzuki et al. Soluble type II transforming growth factor-β receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity
JP7809324B2 (ja) sEphB4-HSA融合タンパク質を用いたがんの治療
CA2962451A1 (en) Treatment of cancer with immune stimulators
Donovan et al. Paracrine activin-A signaling promotes melanoma growth and metastasis through immune evasion
Bukowski et al. Clinical practice guidelines: renal cell carcinoma
CN115232217B (zh) 一种SynNotch结构及其应用
ES2313076T3 (es) Tratamiento y diagnostico de neoplasias usando linfopoyetina estromal timica.
Apte et al. Opposing Effects of IL-1α and IL-1β on Malignancy Patterns: Tumor cell-associated IL-Iα potentiates anti-tumor immune responses and tumor regression, whereas IL-1β potentiates invasiveness
US20210196744A1 (en) Compositions for cancer therapy and methods
US20240288425A1 (en) Selection of patients for combination therapy
US20250177505A1 (en) Cancer vaccine comprising epitope of c-met and epitope of hif1alpha, and use thereof
EP4674421A1 (en) Anticancer agent, pharmaceutical composition for cancer treatment, kit, and activator
KR102654518B1 (ko) Lsp1 결핍 t 세포
Santiesteban Relieving Immune Suppression in the Melanoma Tumor Microenvironment
US20220062390A1 (en) Methods of treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination